Endostar, a novel modified recombinant human endostatin, approved by the China Food and Drug Administration (CFDA) for the treatment of non-small cell lung cancer (NSCLC) in 2005, has showed strong antiangiogenic effect on a variety of xenotrans planted tumors and cancer patients, including NPC [27–32]. Here, COL18A1 is linked to non-small cell lung carcinoma.